FDA Orange Book
Is there a generic for Mounjaro Kwikpen?
Mounjaro Kwikpen contains tirzepatide. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Mounjaro Kwikpen (tirzepatide). The Orange Book shows its last listed patent expires December 30, 2041 and its last listed exclusivity ends December 19, 2028.
Run it in Rivvi
Map Mounjaro Kwikpen and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Mounjaro Kwikpen products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, subcutaneous | 10MG/2.4ML (4.17MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 20MG/2.4ML (8.33MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 30MG/2.4ML (12.5MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 40MG/2.4ML (16.7MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 50MG/2.4ML (20.8MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, subcutaneous | 60MG/2.4ML (25MG/ML) | Marketed (Rx) | None | 0 | None |
NDA 215866, held by ELI LILLY AND CO. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Mounjaro Kwikpen patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9474780 | May 13, 2036 | Drug substance, Drug product | U-4374 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4229 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4232 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4401 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4400 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4231 | 215866 |
| 12343382 | July 22, 2039 | Method of use | U-4230 | 215866 |
| 12616740 | July 22, 2039 | Method of use | U-4500 | 215866 |
| 12616740 | July 22, 2039 | Method of use | U-4501 | 215866 |
| 12616740 | July 22, 2039 | Method of use | U-4502 | 215866 |
| 12295987 | December 30, 2041 | Method of use | U-4192 | 215866 |
| 12295987 | December 30, 2041 | Method of use | U-4193 | 215866 |
Mounjaro Kwikpen exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NCE | New chemical entity | May 13, 2027 | 215866 |
| NPP | New patient population | December 19, 2028 | 215866 |
Mounjaro Kwikpen NDC codes
Questions
Is there a generic for Mounjaro Kwikpen?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Mounjaro Kwikpen (tirzepatide). The Orange Book shows its last listed patent expires December 30, 2041 and its last listed exclusivity ends December 19, 2028.
What is the generic name for Mounjaro Kwikpen?
The active ingredient in Mounjaro Kwikpen is tirzepatide, per the FDA Orange Book.
When does the Mounjaro Kwikpen patent expire?
The last patent listed for Mounjaro Kwikpen in the Orange Book expires December 30, 2041. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.